IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 141 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.41 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,701,025 | -26.6% | 1,692,533 | +13.5% | 0.00% | -33.3% |
| Q2 2023 | $10,498,203 | +62.7% | 1,491,222 | +41.2% | 0.00% | +50.0% |
| Q1 2023 | $6,451,256 | -4.3% | 1,055,852 | +0.1% | 0.00% | 0.0% |
| Q4 2022 | $6,740,453 | -31.5% | 1,054,844 | +2.7% | 0.00% | -50.0% |
| Q3 2022 | $9,844,000 | -10.9% | 1,027,460 | +2.7% | 0.00% | 0.0% |
| Q2 2022 | $11,046,000 | -6.2% | 1,000,472 | +41.4% | 0.00% | 0.0% |
| Q1 2022 | $11,780,000 | -10.0% | 707,496 | +3.2% | 0.00% | 0.0% |
| Q4 2021 | $13,086,000 | -20.3% | 685,459 | +2.9% | 0.00% | -20.0% |
| Q3 2021 | $16,421,000 | -16.5% | 665,896 | -11.9% | 0.01% | -28.6% |
| Q2 2021 | $19,656,000 | -12.4% | 755,416 | +6.6% | 0.01% | -12.5% |
| Q1 2021 | $22,437,000 | -25.5% | 708,658 | +9.1% | 0.01% | -33.3% |
| Q4 2020 | $30,126,000 | +43.2% | 649,257 | +1.6% | 0.01% | +20.0% |
| Q3 2020 | $21,032,000 | +22.5% | 638,870 | +2.1% | 0.01% | +25.0% |
| Q2 2020 | $17,170,000 | -22.7% | 625,487 | -15.7% | 0.01% | -38.5% |
| Q1 2020 | $22,222,000 | +10.0% | 742,310 | +1.8% | 0.01% | +18.2% |
| Q4 2019 | $20,193,000 | +58.3% | 729,497 | +4.1% | 0.01% | +37.5% |
| Q3 2019 | $12,757,000 | -25.9% | 700,933 | -0.2% | 0.01% | -20.0% |
| Q2 2019 | $17,220,000 | +171.1% | 702,254 | +5.2% | 0.01% | +150.0% |
| Q1 2019 | $6,351,000 | +12.4% | 667,774 | +4.6% | 0.00% | 0.0% |
| Q4 2018 | $5,652,000 | +8.7% | 638,580 | +38.2% | 0.00% | +33.3% |
| Q3 2018 | $5,198,000 | -0.2% | 462,016 | +13.6% | 0.00% | -25.0% |
| Q2 2018 | $5,206,000 | -14.0% | 406,692 | +13.6% | 0.00% | -20.0% |
| Q1 2018 | $6,051,000 | +150.2% | 357,995 | +18.5% | 0.01% | +150.0% |
| Q4 2017 | $2,418,000 | +40.5% | 302,175 | +36.1% | 0.00% | 0.0% |
| Q3 2017 | $1,721,000 | +11.9% | 222,015 | +6.2% | 0.00% | +100.0% |
| Q2 2017 | $1,538,000 | – | 209,132 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 565,890 | $26,257,000 | 9.39% |
| Consonance Capital Management LP | 1,710,803 | $79,381,000 | 7.41% |
| GREAT POINT PARTNERS LLC | 917,427 | $42,569,000 | 6.91% |
| Avoro Capital Advisors LLC | 7,500,000 | $348,000,000 | 5.99% |
| Ghost Tree Capital, LLC | 500,000 | $23,200,000 | 5.17% |
| FRAZIER MANAGEMENT LLC | 1,312,999 | $60,923,000 | 4.69% |
| Perceptive Advisors | 9,166,304 | $425,316,000 | 4.56% |
| Ally Bridge Group (NY) LLC | 360,000 | $16,704,000 | 2.86% |
| Orbimed Advisors | 6,645,100 | $308,333,000 | 2.70% |
| ACUTA CAPITAL PARTNERS, LLC | 164,800 | $7,647,000 | 2.08% |